

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

### 34 ABSTRACT



47

48 KEYWORDS:

49 Basophils, T follicular helper cells, autoantibodies, PD-L1, IL-4, Systemic Lupus Erythematosus, lupus 50 nephritis, pathophysiology, pristane, CT-M8.

51

### 53 **INTRODUCTION**



77 Basophils are activated during SLE pathogenesis and accumulate in SLO where they promote 78 autoantibody production by supporting antibody-secreting plasmablast accumulation<sup>10,11</sup>. Depleting 79 basophils in lupus-like mouse models with established disease dampens lupus-like activity by 80 reducing plasmablast numbers, autoantibody titers, CIC deposits in glomeruli, and kidney 81 inflammation<sup>10,11</sup>, thus demonstrating that basophils are responsible for an amplification loop driving 82 the disease to a pathogenic threshold. In agreement, constitutive basophil deficiency prevents lupus-83 like disease onset in the pristane-induced lupus-like disease model<sup>12</sup>. In this context, targeting the 84 addressing of basophils to SLO has demonstrated promising therapeutic potential<sup>11,13</sup>. In the *Lyn<sup>-/-</sup>* 85 lupus-like mouse model, we previously showed that basophils accumulate in SLO where they express 86 surface molecules that suggest interactions with the B and T cell compartments to promote plasma 87 cell maturation and antibody secretion<sup>10</sup>. However, the mechanisms by which basophils, once in SLO, 88 actually promote this disease amplification loop remains unknown. 89 Here, we screened cell surface molecules on blood basophils from SLE patients that could support a 90 functional interaction of these cells with SLO cell partners in the lupus context. We demonstrate *in*  91 *vitro* in humans and *in vivo* in two different SLE mouse models that PD-L1 expression and IL-4 92 production by basophils are required to promote the cross-talk of these cells with TFH cells to sustain 93 TFH cell pathogenic accumulation, TFH2 cell differentiation, and thereby mediate SLE disease onset 94 and progression.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.01.10.23284399;](https://doi.org/10.1101/2023.01.10.23284399) this version posted January 11, 2023. The copyright holder for this

#### It is made available under a CC-BY-NC-ND 4.0 International license.

### 95 **RESULTS**

### 96 **Human blood basophils from SLE patients overexpress PD-L1**

97 TFH, and especially TFH2, cells are significant contributors to the physiopathology of SLE. Proportions 98 among CD4<sup>+</sup> T cells of circulating TFH (cTFH) and cTFH2 cells are increased in several SLE patient 99 cohorts and lupus-like mouse models<sup>4-7,14,15</sup>. We first assessed these cTFH cells (CD3<sup>+</sup> CD4<sup>+</sup> CXCR5<sup>+</sup> 100 ICOS<sup>+</sup> PD-1<sup>+</sup> cells) and cTFH2 cells (CCR6<sup>-</sup> CXCR3<sup>-</sup> TFH cells) in our SLE patient cohort (Table S1) and 101 confirmed both their increased representation among CD4<sup>+</sup> T cells and a cTFH2 cell bias that was 102 associated with disease activity (**Fig. 1a-c**). 103 We and others reported that peripheral basopenia and activation of blood basophils correlate with 104 disease activity in SLE patients<sup>10,11,16</sup>. Our current SLE patient cohort further confirmed this blood

105 basophil phenotype as evidenced by basopenia and overexpression of the activation marker CD203c, 106 the chemokine receptor CXCR4, and the L-selectin CD62L, all of them being associated with disease

107 activity (**Fig. S1a-e** and **Fig. 1d**).

108 To investigate whether, in the SLE context, human basophils were more prone to interact with TFH 109 cells, we assessed the expression levels of several surface markers identified to be relevant 110 interacting molecules with TFH cells. PD-L2, ICOSL, and OX40L were barely detected on the surface of 111 human blood basophils and no difference in their expression levels on basophils from healthy donors 112 or SLE patients was observed (**Table S2**). Nevertheless, PD-L1 was strongly upregulated on the 113 surface of SLE patient blood basophils as compared to healthy donor blood basophils, independently 114 of the activity of the disease (**Fig. 1e** and **Table S2**). In addition, PD-L1 expression on SLE patient 115 blood basophils correlated with the basophil activation status (Spearman r=0.3113, P < 0.0001, n=204) (**Fig. S1f**). CD84, a member of the SLAM family of proteins important for TFH cell regulation<sup>17</sup>. 117 was highly expressed by human basophils (**Fig. S1g** and **Table S2**). Although no significant increase in 118 CD84 expression on blood basophils from the whole SLE patient cohort was found, its expression was

119 significantly increased on blood basophils from active SLE patients as compared to healthy volunteers

### 120 (**Fig. S1g** and **Table S2**).

121 Altogether, these results demonstrated that basophils from SLE patients overexpress PD-L1 and

- 122 CD84, suggesting that a basophil-TFH cell interaction may occur during lupus pathogenesis.
- 123 **Basophil-TFH cell axis in lupus-like mouse models**

124 We next sought to verify whether this increased expression of PD-L1 on basophils from SLE patients

125 was also detected on basophils from lupus-like mouse models in which basophil contribution to

126 disease activity is established<sup>10,11,18</sup>. PD-L1 expression was increased on the surface of basophils from

127 both pristane-induced and *Lyn<sup>-/-</sup>* lupus-like mouse models in the analyzed compartments (blood,

128 spleen, and lymph nodes) (**Fig. 2a,b**). As shown in other human studies and previous reports<sup>7,11</sup>,

129 increased TFH cell proportions among CD4+ T cells and basophil accumulation were observed in both

130 lupus-like mouse models in blood and the secondary lymphoid organs spleen, and lymph nodes (**Fig.** 

131 **2c-f** and **Fig. S2**). These results suggest a positive correlation between basophils and TFH cells during

132 lupus-like disease.

133 To evaluate whether a functional relationship between basophils and TFH cells was taking place

134 during the course of the disease, we depleted basophils through diphtheria toxin injection in

135 Mcpt8<sup>DTR</sup> mice in both lupus-like models during ten days before their analysis (Fig. S2a,b). We

136 previously showed that basophil depletion dampens CD19+CD138+ short-lived plasma cell numbers in

137 SLO, autoantibody titers, kidney deposits and inflammation, and disease activity in these

models10,11,18 138 . Here, in agreement, efficient DT-mediated basophil depletion (**Fig. 2e,f** and **Fig. S2a,b**)

resulted in a dramatic decrease in autoreactive IgG antibody titers in both pristane-induced and *Lyn–* 139

140 <sup>/–</sup> lupus-like mouse models (**Fig. 2g,h**). In addition, it abrogated the increase in TFH cell proportions in

141 blood and SLO from lupus-like mice (**Fig. 2c,d** and **Fig. S2c,d**), strongly suggesting a functional

relationship between the two cell compartments. Of note, basophil depletion in *Lyn–/– Mcpt8* 142 *DTR* mice

143 did not modify the proportion of regulatory TFH (TFR) cells among the TFH cell population (**Fig.**  144 **S3a,b**).

145 We recently showed that basophils play a nonredundant role in pristane-induced lupus-like disease 146 and that basophil-deficient mice ( $McyB^{CT/+}$   $Rosa26^{DTA/+}$  mice) are resistant to pristane-induced lupus-147 like disease onset<sup>12</sup>. The functional relationship between basophils and TFH cells was further 148 confirmed in this mouse model since no increase in the TFH cell proportion was observed in pristane-149 injected basophil-deficient mice as compared to control mice (*Mcpt8<sup>CT/CT</sup> Rosa26<sup>+/+</sup>*) in any of the 150 analyzed compartments (**Fig. 2i**).

151 The functional interaction between the two cell types seemed restricted to the lupus-like

152 environment. Indeed, basophil depletion in WT animals in both models or constitutive basophil

153 deficiency did not modify the basal proportions of TFH cells in the observed compartments (**Fig.** 

154 **2c,d,i**). Moreover, basophils, which are not involved in the humoral response to the ovalbumin (OVA)

155 protein after intraperitoneal immunization in alum<sup>19</sup>, did not influence the rise in TFH cell numbers in

156 these conditions. Indeed, we could measure the induction of TFH cells in OVA-immunized mice which

157 was associated with the production of anti-OVA IgG antibodies but not with the accumulation of

158 basophils in the spleen nor in the draining (mesenteric) lymph node (**Fig. S3c-f**). DT-mediated

159 basophil depletion starting the last 48 hours of the immunization procedure did not modify the TFH

160 cell response nor the anti-OVA IgG titers in immunized mice, suggesting that basophils were not

161 involved in the support of TFH cells in a protein-immunization setting, unlike what we observed in

162 the lupus-like context (**Fig. S3c-f** and **Fig. 2**).

163 Altogether, these data strongly suggest that basophils, by accumulating in SLO, enable the expansion 164 of the TFH cell population in two distinct lupus-like mouse models and that basophils and TFH cells 165 may share a functional relationship in the lupus-like context.

166 **Basophils control TFH cell ability to produce IL-21 and IL-4 in a lupus-like context**

167 We next assessed whether basophils could influence the cytokine production abilities of the 168 expanded TFH cells during the disease. First, the proportions of spleen TFH cells producing IL-21 169 without any restimulation were significantly increased in both lupus-like models and further 170 amplified after phorbol myristate acetate (PMA) and ionomycin restimulation as compared to spleen 171 TFH cells from control mice (**Fig. 3a-c**). This suggested that in the lupus-like context, TFH cells are 172 more prone to provide IL-21 to surrounding cells in these mouse models. Second, the same 173 observations were done concerning IL-4 production by TFH cells showing a TFH2 bias in these two 174 lupus-like models (**Fig. 3d-f**), as was also observed in the SLE patient cohort (**Fig. 1c**). Of note, no such 175 bias was observed for IFNγ production by TFH cells in any of the mouse models (**Fig. 3g,h**). Third, 176 basophil depletion dramatically dampened both constitutive and PMA-ionomycin-induced IL-21 and 177 IL-4 productions by TFH cells only in the lupus-like context, without significantly influencing their IFNγ 178 production ability (**Fig. 3a-h**). These results strongly suggest that, in the lupus-like context, basophils 179 promoted TFH cell-derived IL-21 and IL-4 production ability and were responsible for a TFH2 cell bias 180 of this T cell population.

181 Both IL-6 and IL-4 are involved, respectively, in TFH and TFH2 cell differentiation<sup>7,15</sup>. Basophils are 182 potent producers of these cytokines<sup>20,21</sup>. We next assessed whether basophils in both pristane-183 injected and Lyn-deficient animals were more prone to produce these cytokines with or without 184 PMA-Ionomycin restimulation. Unlike what was observed in basophils from control mice, constitutive 185 IL-4 and IL-6 productions were significantly detected in non-restimulated basophils from both lupus-186 like models, whereas no major differences were noticed after PMA-ionomycin restimulation (**Fig. 3i-**187 **m**). These results suggested that during the course of the disease, along with their increased 188 expression of PD-L1 (**Fig. 2a,b**), basophils produce IL-6 and IL-4 *in vivo* which may explain some of 189 their effects on the expansion of the TFH cell population and its TFH2 cell bias.

190 **Basophils promote** *ex vivo* **TFH cell differentiation through IL-4- and PD-L1-dependent mechanisms** 

191 Next, we evaluated the effects of basophils and basophil-expressed mediators on the differentiation 192 of TFH cells *ex vivo* in a co-culture system. The presence of basophils induced a clear differentiation 193 of the CD3/CD28-activated naïve CD4+ T cells towards the TFH cell subset with an increased ability of 194 these TFH cells to produce IL-21 and IL-6 (**Fig. 4a-c**). Moreover, the basophil-induced TFH cell 195 differentiation was biased towards the TFH2 cell subset as evidenced by an increased ability to 196 produce IL-4 and IL-13 (Fig. 4d,e). We next bred CT-M8 (or *Mcpt8<sup>CT/CT</sup>*) mice<sup>12</sup> with *II4<sup>fI/fl 22*, *II6<sup>fI/fl 23*</sup>, or</sup> 197 Pdl1<sup>*fl/fl* 24</sup> mice and generated mice deficient for IL-4, IL-6, or PD-L1 selectively in the basophil 198 compartment (**Fig. S4a-c**). IL-4-deficient basophils could not induce any of the effects on the TFH cell 199 differentiation as compared to WT basophils (**Fig. 4a-e**). IL-6-deficient basophils could still induce TFH 200 cell differentiation despite reduced IL-6, but increased IL-21, production by TFH cells (**Fig. 4a-c**) and 201 had a limited effect on the TFH2 cell differentiation (**Fig. 4d,e**). Interestingly, PD-L1 expression by 202 basophils was mandatory to induce TFH cell differentiation but had a limited impact on the TFH2 cell 203 differentiation that was completely dependent on basophil-expressed IL-4 (**Fig. 4a-e**). Of note, PMA-204 ionomycin restimulation of the co-cultured cells in the aforementioned conditions led to the same 205 conclusions (**Fig. S4d-g**).

206 Altogether, these results demonstrated that basophils induce *ex vivo* TFH cell differentiation in an IL-

207 4- and PD-L1-dependent manner and that basophil-derived IL-6 is dispensable for these effects.

### **CD4<sup>+</sup>** 208 **T cells promote basophil ability to induce TFH cell differentiation** *ex vivo*

209 In parallel, we analyzed the effects of the CD4<sup>+</sup> T cells on the basophil compartment. The presence of 210 CD4<sup>+</sup> T cells up-regulated PD-L1 expression on basophils and induced constitutive IL-4, IL-6, and IL-13 211 productions by these cells (Fig. 4f-k). The CD4<sup>+</sup> T cell-induced up-regulation of PD-L1 on basophils 212 was partially dependent on the IL-4 produced by basophils themselves, but independent of basophil-213 derived IL-6 (Fig. 4f,g). Conversely, the CD4<sup>+</sup> T cell-induced IL-4 (and IL-6) production by basophils 214 was partially dependent on PD-L1 expressed by basophils without impacting their maximal 215 production ability (**Fig. 4h-i**, and **Fig. S4h,i**). IL-6 deficiency in basophils did not alter their ability to

216 produce IL-4 constitutively in the presence of CD4<sup>+</sup> T cells nor after PMA-ionomycin restimulation but 217 enhanced their IL-13 production only in the former situation (**Fig. 4h-k** and **Fig. S4h-j**). These results 218 suggest that PD-L1 engagement on basophils by CD4<sup>+</sup> T cells, beyond promoting IL-21 production by 219 TFH cells (**Fig. 4b**), was responsible for the extent of T cell-induced cytokine production by basophils. 220 This may explain why PD-L1 deficient basophils could not promote TFH cell differentiation (**Fig. 4a**). 221 Of note, CD4<sup>+</sup> T cells induced IL-13 production by basophils and enhanced their maximal ability to 222 produce this cytokine independently of their IL-4 or PD-L1 expression (**Fig. 4k** and **Fig. S4j**). Altogether, these results strongly suggest that a bi-directional interaction between naïve CD4+ T cells 224 and basophils leads to the differentiation of TFH cells via a mechanism mainly depending on IL-4 and 225 PD-L1 expression by basophils but independent of the basophil-derived IL-6. 226 **PD-L1 controls the basophil-TFH cell functional relationship during lupus-like disease** 227 We next sought to validate *in vivo* the relevance of PD-L1 expression by basophils in their functional 228 relationship with TFH cells in the lupus-like context. Pristane injection did not lead to TFH cell accumulation in SLO in mice with basophil-restricted PD-L1-deficiency (*Mcpt8CT/+ Pdl1fl/fl* 229 ) as compared to WT animals (*Mcpt8CT/+* 230 ) (**Fig. 5a** and **Fig. S5**). However, PD-L1 expression by basophils 231 was not required for basophil accumulation in SLO (**Fig. 5b**). Both the lupus-like context *in vivo* (**Fig.**  232 **3l,m**) and the co-culture system *in vitro* (**Fig. 4h-k**) induced IL-4 and IL-6 production by basophils. 233 Here, PD-L1 deficiency on basophils completely prevented these cytokine basal productions in the lupus-like context (**Fig. 5c,d**). This was associated with a non-expansion of CD19<sup>+</sup>CD138<sup>+</sup> 234 cells in SLO 235 (**Fig. 5e**) leading to dramatically reduced anti-RNP autoreactive IgG titers in the blood (**Fig. 5f**). 236 Moreover, increased IgG and C3 glomerular deposits were barely detectable in the kidney of 237 pristane-injected *Mcpt8<sup>CT/+</sup>* Pdl1<sup>fl/fl</sup> mice as compared to their WT counterparts (Fig. 5g,h). 238 Altogether, these results strongly suggest that PD-L1 basophil expression and up-regulation during 239 lupus development were not involved in basophil accumulation in SLO but were responsible for the

240 basophil-induced promotion of TFH and short-lived plasma cell expansions and subsequent

241 pathological parameters.

### 242 **Basophil-derived IL-4 exerts a dual effect during lupus-like disease development**

243 Since TFH cell differentiation *ex vivo* depended on IL-4 expression by basophils (**Fig. 4**), we next 244 sought to verify whether basophil-derived IL-4 was mandatory for the basophil-TFH cell functional 245 relationship in the lupus-like context. As suggested above, IL-4 deficiency selectively in the basophil 246 compartment (*Mcpt8<sup>CT/+</sup> Il4<sup>fl/fl</sup>*) prevented the pristane-induced TFH cell accumulation in SLO as 247 compared to WT (*Mcpt8<sup>CT/+</sup>*) animals (**Fig. 6a**). By contrast, basophil recruitment into SLO upon 248 pristane treatment of the mice was not dependent on basophil-derived IL-4 since basophil accumulation in these locations in mice was similar in *Mcpt8CT/+ Il4fl/fl* and *Mcpt8* 249 *CT/+* WT animals (**Fig. 6b**). Surprisingly, CD19<sup>+</sup>CD138<sup>+</sup> 250 cells still accumulated in SLO despite selective basophil IL-4 deficiency 251 (**Fig. 6c**). This phenotype was associated with a still significant constitutive IL-6 production by IL-4- 252 deficient basophils in the lupus-like context (**Fig. 6d**). However, no significant titers of anti-RNP IgG autoantibodies were detected in the blood of pristane-injected *Mcpt8CT/+ Il4fl/fl* 253 mice as compared to 254 their WT counterparts. In line with this feature, no IgG deposits were present in the glomeruli of 255 pristane-treated mice with basophil-specific IL-4 deficiency but C3 deposits, although reduced, were 256 still detected (Fig. 6f and Fig. S6a,b). Along with the accumulation of CD19<sup>+</sup>CD138<sup>+</sup> cells in the SLO, the latter result led us to assess the presence of autoreactive IgM in the pristane-treated *Mcpt8CT/+* 257 258 *II4<sup>fl/fl</sup>* mice. As suspected, increased titers of anti-RNP IgM in the plasma of mice with IL-4 deficient basophils were observed as compared to pristane-treated *Mcpt8* 259 *CT/+* WT mice (**Fig. 6g**). These 260 autoreactive IgM were not detected in the blood from pristane-injected basophil-specific PD-L1- 261 deficient mice nor constitutive basophil-deficient mice (**Fig. 6g**) in line with the absence of 262 plasmablast accumulation in SLO from these mice (Fig. 5e and <sup>12</sup>). These anti-RNP IgM titers 263 correlated with the presence of IgM deposits in the glomeruli of the corresponding mice (**Fig. 6h,i**).

264 Altogether, these results strongly suggest that TFH cell pathogenic accumulation in SLO and 265 autoreactive IgG titers induced by pristane were dependent on the basophil-derived IL-4. However, CD19<sup>+</sup>CD138<sup>+</sup> 266 short-lived plasma cell accumulation, which is dependent on basophils (**Fig. 2** and  $11,12,18$ , was not dependent on IL-4 production by basophils. This led to an accumulation of plasmatic 268 autoreactive anti-RNP IgM, with no IgG deposits but increased C3 deposits in glomeruli of the 269 Mcpt $8^{CT/4}$  Il4<sup>*fl/fl*</sup> mice, suggesting that basophil-derived IL-4 was both enabling autoreactive antibody 270 switch towards the IgG isotype and TFH cell accumulation that promoted this phenomenon as 271  $well^{7,15}$ .

## 272 **Human basophils drive** *ex vivo* **TFH cell and TFH2 cell differentiation through IL-4, IL-6, and PD-1-** 273 **dependent mechanisms**

274 We next sought to validate the ability of basophils to promote TFH cell differentiation in a human co-275 culture system. First, CD3- and CD28-activated human naïve CD4<sup>+</sup> T cells were cultured for three days 276 without or with increasing numbers of purified human basophils demonstrating the capacity of 277 human blood basophils to induce TFH cell differentiation (**Fig. 7a-c)** more potently than mouse 278 spleen basophils (Fig. 4a). Next, cultures of CD3- and CD28-activated human naïve CD4<sup>+</sup> T cells alone 279 or together with basophils were repeated in the presence of blocking antibodies targeting IL-4, IL-6, 280 PD-1, or their corresponding isotype controls. As seen in the murine system, IL-4 and PD-1 antagonisms led to a dramatic decrease in the ability of human basophils to drive CD4+ T cell 282 differentiation into TFH cells (**Fig. 7d**). IL-6 blockade also decreased basophil-induced TFH cell 283 differentiation, probably due to its effects on the T cell-derived IL-6 (**Fig. 7d**). Most of the basophil-284 induced TFH cells were belonging to the TFH2 cell subset expressing neither CCR6 nor CXCR3 (**Fig.**  285 **7e,f**). This TFH2 cell subset differentiation was dramatically dampened by the blockade of IL-4, IL-6, 286 or PD-1 (**Fig. 7e,f**).

Altogether, these data demonstrate that human basophils could induce human naïve CD4+ T cell 288 differentiation into TFH cells, especially into the TFH2 cell subset, and that this was dependent on IL-

- 289 4 and PD-1. Together with the PD-L1 overexpression by blood basophils from SLE patients (**Fig. 1e**),
- 290 these results strongly suggest that, as demonstrated in the lupus-like mouse models (**Figs. 2-6)**,
- 291 basophils promote the pathogenic accumulation of TFH cells during SLE pathogenesis through their
- 292 expression of PD-L1 and IL-4.

### 293 **DISCUSSION**



307 The impairment of this basophil-dependent pathogenic accumulation of TFH cell in SLO led to a 308 dramatic reduction in autoreactive anti-RNP IgG production and IgG kidney deposits, further 309 validating the relevance of both cell types in autoantibody and pathogenic CIC productions in a lupus-310 like context. Investigating whether basophils control spontaneous EF TFH cell responses in other 311 autoimmune diseases such as rheumatoid arthritis or multiple sclerosis may lead to developing 312 common therapeutic strategies for these different autoimmune conditions that may share some 313 . pathophysiological pathways $26$ .

314 Recently, Kim *et al.* showed that TFH2 cells are induced by, and produce some, IL-4. These TFH2 cells 315 are central in humoral autoimmunity, promote autoreactive IgE production with their frequencies 316 increased in both SLE patients and also some SLE-like mouse models<sup>15</sup>. Accordingly, systemic IL-4 817 blockade dampened TFH2 cell accumulation and their deleterious effects in the *Ets1<sup>ΔCD4</sup>* lupus-like

318 mouse model. As exogenous IL-4 induces Gata3 expression in T cells enabling TH2 cell 319 differentiation<sup>27</sup>, exogenous IL-4 enabled Gata3<sup>+</sup> TFH2 cell accumulation in an SLE-like context in a 320 similar way<sup>15</sup>. Our data strongly suggest that basophils deliver the required IL-4-induced priming to 321 CD4<sup>+</sup> T cells in a PD-L1-dependent manner that allows TFH and TFH2 cell accumulation in the lupus-322 like context. Further studies will be required to validate this feature in other lupus-like mouse models 323 including *Ets1<sup>* $\Delta$ *CD4*</sup> mice. This IL-4 mediated basophil-TFH pathogenic axis is important since basophil 324 depletion may represent a safer therapeutic strategy than global IL-4 neutralization. Indeed, this 325 cytokine controls a large number of physiologically protective processes<sup>28,29</sup> and other deleterious 326 pathways involved in SLE pathophysiology may limit the benefits for the patients of long-term IL-4 327 blockade<sup>2</sup>.

Both human and murine basophils promoted CD3/CD28 activated naïve CD4<sup>+</sup> T cell differentiation 329 into TFH cells *ex vivo* in the absence of specific antigen or recognized potent antigen-presenting cells. 330 These effects depended on basophil-expressed IL-4 and PD-L1 (but not on IL-6) for murine cells and 331 were dampened by IL-4, IL-6, or PD-1 blocking antibodies for human cells. This setting may resume spontaneous TFH cell responses occurring in the SLE context<sup>7</sup>. TCR repertoire analysis of these 333 basophil-induced TFH cells may help to decipher whether these spontaneous TFH cell responses 334 favor autoreactivity of the TFH cell compartment.

335 pDC and type I IFN have recently been shown to promote EF T-dependent B cell responses to 336 extracellular self DNA<sup>30</sup>. Our data suggest that basophils and their PD-L1 expression are mandatory to 337 induce TFH cell pathogenic accumulation and B cell response to nuclear antigens. PD-L1 expression 338 by CD11c-expressing cells inhibits TFH cell response in experimental autoimmune 339 encephalomyelitis<sup>31</sup>. Type I IFN promotes human basophil apoptosis, but this effect is rescued by IL-340  $3^{32}$  whose production (mainly by T cells<sup>33</sup>) is increased during SLE pathogenesis<sup>34,35</sup> and acts as well 341 on pDC survival<sup>36</sup>. Thus, it may be relevant to study the interplay between basophils and DC subsets 342 in this process. pDC or follicular DC and basophils may indeed compete to engage PD-1 on TFH cells

343 to respectively inhibit or promote TFH cell expansion and TFH2 cell differentiation in EF responses in 344 an autoimmune context.

345 PD-L1 expression by basophils is known in humans and may be induced by  $IFNv^{37}$ . PD-L1 upregulation 346 on human basophils has recently been described during SARS-CoV2 infections<sup>38</sup> although it is not 347 directly induced by the virus<sup>39</sup>. Interestingly, basopenia occurs in acute SARS-CoV2 infection 348 suggesting putative recruitment of basophils to SLO<sup>40</sup>. This hypothesis is further supported by 349 basophil overexpression of CXCR4 and CD62L in the SARS-CoV-2 infection setting, similar to what we 350 described in SLE patients<sup>10,11,40,41</sup>. Normalization of both blood basophil numbers and activation 351 markers is associated with the humoral response and recovery of COVID-19 patients<sup>40,42</sup>. This may 352 indicate a role for PD-L1-overexpressing basophils in TFH cell induction to promote antiviral humoral 353 response. EF responses occurring in lupus-prone mice and during some infections can quickly 354 involute if new plasmablasts are not generated<sup>25</sup>. Thus, controlling basophil function or localization in 355 SLO during viral infections may represent interesting therapeutic strategies to promote or sustain the 356 antiviral humoral response. 357 Unexpectedly, when injected with pristane, mice with IL-4-deficient basophils still showed some

358 plasmablast accumulation in SLO and C3 kidney deposits despite the absence of TFH cell 359 accumulation, anti-RNP IgG induction, and IgG kidney deposits. Unlike pristane-injected basophildeficient mice or mice with PD-L1-deficient basophils, *Mcpt8CT/+Il4fl/fl* 360 mice developed high titers of 361 anti-RNP IgM. This indicates that basophils express factors other than IL-4 in SLO during lupus-like 362 disease responsible for their PD-L1-dependent action on B cell maturation into plasmablast in the 363 absence of TFH cell pathogenic accumulation. However, it strongly suggests as well that basophil-364 derived IL-4 is mandatory for autoantibody class switch towards IgG in the lupus-like context. Further 365 characterization of this B cell–basophil relationship in SLO in the SLE context will be required to 366 identify basophil-derived factors that contribute to TFH-independent plasmablast proliferation.

- 367 Our study establishes a direct link between basophils and TFH cells in the SLE context that promotes
- 368 autoreactive IgG production and lupus nephritis pathogenesis. Altering the basophil/TFH cell axis in
- 369 the SLE context may represent a promising innovative intervention strategy in SLE.

### 371 **Acknowledgments**

372 This work was supported by the Fondation pour la Recherche Médicale (FRM) [grant # 373 EQU201903007794] to N.C., the French Agence Nationale de la Recherche (ANR) [grants # ANR-19- 374 CE17-0029 BALUMET to N.C. and ANRPIA-10-LABX-0017 INFLAMEX], the Ministerio de Economía y 375 Competitividad y Fondo Europeo de Desarrollo Regional (RTI2018-101105-B-I00) to J.H., by the 376 Centre National de la Recherche Scientifique (CNRS), by Université Paris-Cité and by the Institut 377 National de la Santé et de la Recherche Médicale (INSERM). We acknowledge the expert work from 378 the members of the animal core facility (I. Renault and S. Olivré), the flow cytometry core facility (G. 379 Gautier, J. Da Silva and V. Gratio) and the imaging facility (S. Benadda) of the Centre de Recherche 380 sur l'Inflammation (INSERM UMR1149), and the help from O. Thibaudeau and L. Wingertsmann from 381 the morphology core facility (INSERM UMR1152).

### 382 **Authors' contributions**

383 J.T. designed experiments, conducted experiments, and wrote the manuscript. N.C. conceived the 384 project, designed experiments, conducted experiments, wrote the manuscript, and directed the 385 project. Q.S., L.C., Y.L., F.S., E.P., J.B-C, C.P., U.B., M.B., G.H., K.S., and E.D. conducted experiments, 386 analyzed the data, and/or edited the manuscript. H.K. and K.M. provided the *II4<sup>fI/fl</sup>* and *Mcpt8*<sup>DTR</sup> mice 387 and edited the manuscript. J.H. provided the *II6<sup>f/f|</sup>* mice and edited the manuscript. P.G.F. provided 388 the *PdI1<sup>f//fl</sup>* mice and edited the manuscript. N.C. had full access to all of the data in the study and 389 take responsibility for the integrity of the data and the accuracy of the data analysis. All authors 390 approved the final version of the article.

### 391 **Declaration of interests:**

- 392 N.C. holds a patent related to compositions and methods for treating or preventing lupus
- 393 (W020120710042). C.P. and N.C. are coinventors of the patent WO2016128565A1 related to the use
- 394 of PTGDR-1 and PTGDR-2 antagonists for the prevention or treatment of systemic lupus
- 395 erythematosus. No other disclosures relevant to this article are reported.

### 396 **FIGURE TITLES AND LEGENDS**

#### 397 **Figure 1: Human blood basophils from SLE patients overexpress PD-L1**

- 398 (**a**) Flow cytometry gating strategy used to identify human circulating T follicular helper T cells (TFH) 399 defined as CD3<sup>+</sup> CD8α<sup>-</sup> CD4<sup>+</sup> CXCR5<sup>+</sup> ICOS<sup>+</sup> PD-1<sup>+</sup>. Among TFH cells, TFH1 cells were defined as 400 CXCR3<sup>+</sup>CCR6<sup>-</sup>, TFH2 as CXCR3<sup>-</sup> CCR6<sup>-</sup>, and TFH17 as CXCR3<sup>-</sup> CCR6<sup>+</sup>. (b) Proportions (%) among CD4<sup>+</sup> T 401 cells of TFH as defined in (**a**) in blood from healthy controls (CT) and inactive (inact.), mild, or active 402 SLE patients (n = 16/11/12/21, respectively) as determined by flow cytometry. (**c**) Proportions (%) among CD4<sup>+</sup> 403 T cells of TFH2 as defined in (**a**) in blood from healthy controls and inactive, mild, or 404 active SLE patients (n = 16/10/12/20, respectively) as determined by flow cytometry. (**d**) **Left**, 405 Histogram plot representing the CD203c expression levels on blood basophils from a healthy control 406 (CT, black line), a patient with active SLE (red line), and isotype control staining (grey filled 407 histogram). **Right**, CD203c expression levels on blood basophils from CT and inact., mild or active SLE 408 patients (n = 43/61/46/98, respectively) as determined by flow cytometry. (**e**) **Left**, Representative 409 histogram plot of PD-L1 expression levels on blood basophils as in (**d**). **Right**, PD-L1 expression levels 410 on blood basophils from CT and inact., mild or active SLE patients (n = 39/60/45/96, respectively) as 411 determined by flow cytometry. (**b**-**e**) Data are presented as violin plots with median (plain line) and 412 quartiles (dotted lines). Statistical analyses were Kruskal-Wallis tests followed by Dunn's multiple 413 comparisons tests. NS: not significant, \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*\*P < 0.0001. A.U.: 414 arbitrary units.
- 415

### 416 **Figure 2: Basophil-TFH functional relationship during lupus-like disease**

(**a**) PD-L1 expression levels on basophils from PBS-injected (blue bars) or pristane-injected *Mcpt8DTR* 417 418 mice (red bars) in the indicated compartments as determined by flow cytometry using the gating 419 strategy described in **Fig. S2a,b**. A representative FACS histogram of PD-L1 expression on spleen 420 basophils from a PBS-injected mouse (blue line), a pristane-injected mouse (red line), and the signal

421 from the isotype control (grey filled) is shown. (**b**). PD-L1 expression levels on basophils from an aged *A22 Mcpt8<sup>DTR</sup>* (blue bars) or aged *Lyn<sup>-/-</sup> Mcpt8<sup>DTR</sup>* mice (red bars) in the indicated compartments as in (**a**). A representative FACS histogram of PD-L1 expression on spleen basophils from an aged *Mcpt8DTR* 423 424 (blue line), an aged *Lyn<sup>-/-</sup> Mcpt8<sup>DTR</sup>* mouse (red line), and the signal from the isotype control (grey 425 filled) is shown. (c) Proportions (%) of TFH among CD4<sup>+</sup> T cells in the indicated compartments from 426 PBS-injected (blue bars) and basophil sufficient (DT–) or basophil-depleted (DT+) mice and from 427 pristane-injected *Mcpt8<sup>DTR</sup>* mice (red bars) DT treated or not. Data were determined by flow 428 cytometry using the gating strategy described in Fig. S2c,d. (d) Proportions (%) of TFH among CD4<sup>+</sup> T cells in the indicated compartments from aged *Mcpt8DTR* 429 (blue bars) and basophil sufficient (DT–) or basophil-depleted (DT+) mice and from aged *Lyn–/– Mcpt8DTR* 430 mice (red bars) DT-treated or not. Data 431 were determined by flow cytometry as in (**c**). (**e**) Proportions (%) of basophils in the indicated 432 compartments in the same mice as described in (**c**) were determined by flow cytometry as in (**a**). (**f**) 433 Proportions (%) of basophils in the indicated compartments in the same mice as described in (**d**) 434 were determined by flow cytometry as in (**a**). (**g**) Anti-RNP IgG autoantibody plasma titers from the 435 same mice as in (**c**) were quantified by ELISA, as described in the methods section. O.D. values at 450 A36 mm were determined and data were normalized to the mean of PBS-injected DT – *Mcpt8<sup>DTR</sup>* values. 437 (**h**) Anti-dsDNA IgG autoantibody plasma titers from the same mice as in (**d**) were quantified by ELISA, 438 as described in the methods section. O.D. values at 450 nm were determined and data were normalized to the mean of DT – *Mcpt8DTR* 439 values. A.U.: arbitrary units. (**i**) Proportions (%) of TFH 440 among CD4<sup>+</sup> T cells in the indicated compartments from basophil-sufficient (*Mcpt8<sup>CT/CT</sup> R26<sup>+/+</sup>*) (blue 441 bars) or basophil-deficient (*Mcpt8<sup>CT/+</sup> R26<sup>DTA/+</sup>*) (red bars) mice treated with PBS or pristane (pristane 442 – or +, respectively). Data were determined by flow cytometry as in (**c**). (**a-i**) Results are from at least 443 three independent experiments and presented as individual values in bars representing the mean 444 values. Statistical analyses were done by one-way ANOVA followed by Holm-Šídák's multiple 445 comparisons test between the indicated groups. NS: not significant, p>0.05; \*: p<0.05; \*\*: p<0.01; 446 \*\*\*: p<0.001; \*\*\*\*: p<0.0001.

It is made available under a CC-BY-NC-ND 4.0 International license.

447

### 448 **Figure 3: Basophils control TFH abilities to produce IL-21 and IL-4 in the lupus-like context**



472

### A Figure 4: A bidirectional crosstalk between basophils and CD4<sup>+</sup> T cells promotes *ex vivo* TFH

### 474 **differentiation**

(**a**-**k**) Purified wild-type naïve CD4<sup>+</sup> 475 T cells were cultured in plates coated with anti-CD3 and anti-CD28 476 antibodies for three days without (–, grey filled bars) or with purified basophils from the following mice: *Mcpt8CT/+* (WT) (blue filled bars), *Mcpt8CT/+ Il4fl/fl* (*Il4fl/fl* 477 , IL-4-deficient basophils) (red filled bars), *Mcpt8CT/+ Il6fl/fl* (*Il6fl/fl*, IL-6-deficient basophils) (orange filled bars), or *Mcpt8CT/+ Pdl1fl/fl* (*Pdl1fl/fl* 478 , PD-L1- 479 deficient basophils) (green filled bars). (a) Proportions (%) of TFH among CD4<sup>+</sup> T cells after three days 480 of culture as described in **methods**. (**b**-**e**) Proportions (%) of IL-21- (**b**), IL-6- (**c**), IL-4- (**d**), and IL-13- (**e**) 481 producing cells among TFH cells non-restimulated and incubated with brefeldin A for the last 4 hours 482 of the culture. (**f**) Representative histograms of PD-L1 expression on purified spleen basophils, from 483 mice with the indicated genotype, co-cultured for three days without (dotted lines) or with activated 484 naïve CD4 T cells (solid lines) (as described above). (**g**) PD-L1 expression levels on basophils, from 485 mice as described above, cultured without (–, light colors) or with (+, dark colors) purified wild-type A86 CD3/CD23-activated naïve CD4<sup>+</sup> T cells for three days. (**h**) Representative contour plots showing IL-6 487 and IL-4 spontaneous production of basophils of the indicated genotype after three days of culture 488 without (–) or with activated CD4+ T cells and in the presence of brefeldin A for the last 4 hours of 489 culture. (**i**,**j**,**k**) Proportions (%) of spontaneous IL-4- (**i**), IL-6- (**j**), and IL-13- (**k**) producing cells among 490 basophils of the indicated genotypes cultured as described above. (**a**-**k**) Results for the same cells but 491 re-stimulated with PMA and ionomycin are shown in **Fig. S4d-j**. (**a**-**e**, **g**, **i**-**k**) Results are from at least 492 three independent experiments and presented as individual values in bars representing the mean  $\pm$ 493 s.e.m.. (**a**) Statistical analyses were done by a Kruskal-Wallis test followed by Dunn's multiple 494 comparisons tests. (**b**-**e**, **g**, **i**-**k**) Statistical analyses were done by Mann-Whitney U test between the 495 indicated groups. NS: not significant, p>0.05; \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001; \*\*\*\*: p<0.0001.

### 497 **Figure 5: PD-L1 controls the basophil-TFH functional relationship during lupus-like disease**



514

# 515 **Figure 6: Basophil-derived IL-4 controls T-dependent autoreactive antibody isotype switch in lupus-**516 **like disease**

517 (a) Proportions (%) of TFH among CD4<sup>+</sup> T cells in spleen (left) and lymph nodes (right) from *Mcpt8<sup>CT/+</sup>* 518 (WT) (blue filled bars) or *Mcpt8<sup>CT/+</sup> II4<sup>fl/fl</sup>* (*II4<sup>fl/fl</sup>*) (red filled bars) mice injected with PBS (-) or with 519 pristane (+). (b) Proportions (%) of basophils among CD45<sup>+</sup> cells in the spleen (left) and lymph nodes 520 (right) from the mice described in (a). (c) Proportions (%) of CD19<sup>+</sup>CD138<sup>+</sup> cells among CD45<sup>+</sup> cells the 521 in the spleen (left) and lymph nodes (right) from the mice described in (**a**). (**d**) Proportions (%) of

522 spontaneous IL-6<sup>+</sup> cells among basophils in the spleen from the mice described in (a) incubated 4 523 hours in the presence of brefeldin A. (**e**) Anti-RNP IgG autoantibody plasma levels from the same 524 mice as in (**a**) were quantified by ELISA, as described in the methods section. O.D. values at 450 nm 525 were determined and data were normalized to the mean of PBS-injected *Mcpt8<sup>CT/+</sup>* values. (**f**) 526 Quantification of C3 (left) and IgG (right) glomerular deposits in kidneys from the mice described in 527 (**a**). A representative picture for each genotype in each condition is shown in **Fig. S6a,b**. (**a**-**f**) The data 528 shown that concerns *Mcpt8<sup>CT/+</sup>* (WT) mice are the same as the data shown in **Fig. 5**. (g) Anti-RNP IgM 529 autoantibody plasma levels were determined by ELISA, as described in the methods section. O.D. 530 values at 450 nm were determined and data were normalized to the mean of the values of PBSinjected control mice for each genotype. The mice analyzed were *Mcpt8CT/+* (WT), *Mcpt8CT/+ Il4fl/fl* 531 532 (*II4<sup>f//fl</sup>), Mcpt8<sup>CT/+</sup> PdI1<sup>f//fl</sup> (PdI1<sup>f//fl</sup>) (green filled bars) and basophil-deficient (<i>Mcpt8<sup>CT/+</sup> R26<sup>DTA/+</sup>*) 533 ( $R26^{DTA/+}$ , grey filled bars) mice treated with PBS or pristane (pristane – or +, respectively). (**h**) 534 Representative pictures of kidneys from mice with the indicated genotypes injected with PBS or 535 pristane showing the intensity of anti-IgM staining by immunofluorescence. Scale bar = 200 µm. (**i**) 536 Quantification of IgM glomerular deposits in kidneys from the mice described in (**g**). (**a**-**i**) Results are 537 from at least three independent experiments and presented as individual values in bars representing 538 the mean values. (**a**-**g**,**i**) Statistical analyses were done by unpaired Student t-tests between the 539 indicated groups. NS: not significant, p>0.05; \*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001; \*\*\*\*: p<0.0001.

540

### 541 **Figure 7: Human basophils drive TFH differentiation through IL-4, IL-6, and PD-L1 dependent**  542 **mechanisms** *ex vivo*

143 (a,b) Representative contour plots showing CD3/CD28-activated human CD4<sup>+</sup> T cells cultured for 544 three days without (**a**) or with (**b**) purified human basophils at a 5:1 ratio (left panels) and the 545 condition-induced TFH differentiation of the CD4+ T cells (right panels). Basophils were defined as 546 FcεRIα<sup>+</sup> CRTH2<sup>+</sup> CCR3<sup>+</sup> cells and TFH cells were defined as CD4<sup>+</sup> PD1<sup>+</sup> CXCR5<sup>+</sup> ICOS<sup>+</sup> cells. (c)



561

### 563 **MATERIAL AND METHODS**

### 564 **Patients**



576 **Mice** 



- 587 comité d'éthique Paris Nord N°121 and the Ministère de l'enseignement supérieur, de la recherche
- 588 et de l'innovation under the authorization number APAFIS#14115.

### 589 **Human samples handling**

- 590 Heparinized human blood samples were centrifuged at 600 g for 5 minutes and 2 mL of plasma were
- 591 collected and stored at -80°C for later analysis. Red blood cells (RBC) were lysed in RBC lysing buffer
- 592 (150 mM NH4Cl, 12 mM NaHCO3, 1 mM EDTA, pH 7.4) in a ratio of 5mL of blood for 20mL of ACK
- 593 lysing buffer. After 5 min of incubation at room temperature (rt), 25mL of PBS were added and cells
- 594 were centrifuged at 600 g for 5 min, and the supernatant was discarded. This procedure was
- 595 repeated 3 times. Leukocytes were then resuspended in fluorescence-activated cell sorting (FACS)
- 596 buffer (PBS 1% BSA, 0.01% NaN3, 1mM EDTA) and prepared for flow cytometry (see below).
- 597 Leukocyte count and viability (>95%) were assessed by trypan-blue staining on a Malassez
- 598 hemacytometer.
- 599 **Pristane-induced lupus-like mouse model**
- 600 Pristane-induced lupus-like disease was initiated by injecting 500  $\mu$ L of 2,6,10,14-
- 601 tetramethylpentadecane or Pristane (Sigma) into the peritoneal cavity of 7-10 weeks-old female
- 602 mice. For control individuals, genotype- and age-matched female mice were injected with 500 µL of
- 603 phosphate buffer saline pH 7.4 (PBS) (Gibco). Mice were attributed to PBS- or pristane-injected
- 604 groups randomly and maintained in the same cage for the whole procedure. Pristane- and PBS-
- 605 injected mice were analyzed 8 weeks after injection.

### 606 **DT-mediated basophil depletion in lupus-like context**

- For diphtheria toxin (DT)-mediated basophil depletion, *Mcpt8DTR*, and *Lyn—/— Mcpt8DTR* 607 mice were
- 608 injected intraperitoneally with 100 µL of PBS containing (or not) 1 µg of DT (Sigma) 10, 9, 6, 2 and 1
- 609 day before the sacrifice.
- 610 **Mouse OVA immunization experiments**

611 10 to 15 weeks old C57/BL6J *Mcpt8<sup>DTR</sup>* sex-matched mice were immunized by intraperitoneal 612 injection of 200 µL of a 50/50 emulsion of Alum (Thermofisher Scientific) with 100 µg of ovalbumin 613 (OVA, Sigma-Aldrich) diluted in PBS or with PBS alone for control mice. A similar injection was 614 performed on day 7 and the mice were sacrificed on day 14. For DT-mediated basophil depletion, 1 615 µg of DT (or PBS as a control) was injected intraperitoneally on day 12 and day 13.

### 616 **Mouse samples processing**

617 Mice were euthanized in a controlled  $CO<sub>2</sub>$  chamber (TEM Sega) and blood sampling was performed 618 through cardiac puncture with a heparin-coated syringe with a 25G needle. Blood was centrifuged at 619 300 g for 15 min and plasma was harvested and kept at -80°C for later analysis. RBC were lysed in 620 5mL of RBC lysing buffer for 5 min at rt and washed with 10mL of PBS. This procedure was repeated 3 621 times and cells were resuspended in PBS. The left kidney was harvested and embedded in OCT 622 embedding matrix (Cellpath) and snap-frozen in liquid nitrogen and kept at -80°C for later analysis. 623 Spleen and lymph nodes (cervical, brachial and inguinal) were harvested in PBS and dissociated by 624 mechanical disruption on a 40 μm cell strainer (Falcon, Corning). For splenocytes, RBC were lysed 625 once in 5mL RBC lysing buffer 5 min at rt and washed with 10mL of PBS. Cell counts were assessed by 626 trypan-blue staining on a Malassez hemacytometer and 1 to 5 million cells were used per FACS 627 staining condition.

### 628 *Ex vivo* **stimulation of splenocytes.**

629 Mouse splenocytes were harvested as described above and resuspended at 5 million cells/mL in 630 culture medium (RPMI 1640 with Glutamax and 20mM HEPES, 1mM Na-pyruvate, non-essential 631 amino acids 1X (all from Life Technologies), 100 μg/mL streptomycin and 100 U/mL penicillin (GE 632 Healthcare) and 37.5 μM β-mercaptoethanol (Sigma-Aldrich) supplemented with 20% heat-633 inactivated fetal calf serum (FCS) (Life Technologies)). For phorbol-myristate-acetate (PMA) and 634 ionomycin stimulation experiments, whole splenocytes were stimulated or not with 40 nM of PMA 635 and 800 nM ionomycin for 4 hours in the presence of 2 µg/mL of brefeldin A (all from Sigma Aldrich,

636 Merck) and cultured at 37°C and 5% CO2. Then, cells were harvested by repeated flushing, and wells 637 were washed with 1mL of PBS. Samples were then prepared for flow cytometry analysis.

### 638 **Flow cytometry staining**

639 For human leukocytes, non-specific antibody binding sites were saturated with 20 µL of a solution 640 containing 100 µg/mL of human, mouse, rat, and goat IgG (Jackson ImmunoResearch Europe and 641 Innovative Research Inc.) in FACS buffer. 200 µL of staining solution containing the panel of 642 fluorophore-conjugated specific antibodies or their fluorophore-conjugated isotypes (described in 643 the **antibodies and reagents table**) were added to the cells for 30 min at 4°C protected from light. 644 After a wash in PBS, cells were fixed in fixation buffer (Biolegend) for 20 minutes at 4°C and then 645 washed in FACS buffer before data acquisition. For mouse samples, cells washed in PBS were stained 646 with GHOST 510 viability dye (TONBO) following the manufacturer's instructions. Non-specific 647 antibody binding sites were saturated with 10 µg/mL of anti-CD16/CD32 antibody clone 2.4G2 648 (BioXCell), and 100 µg/mL of polyclonal rat, mouse, and Armenian Hamster IgG (Innovative Research 649 Inc.) in FACS buffer and stained with the antibodies described in the **antibodies and reagents table** 650 for 30 min in the dark at 4°C. Cells were then washed in FACS Buffer before data acquisition. For 651 intracellular staining, cells were first stained extracellularly as described above. Cells were washed in 652 PBS and fixed with fixation buffer for 20 min at 4°C. Cell permeabilization and intracellular staining 653 were realized with permeabilization/wash buffer (Biolegend) following the manufacturer's 654 instructions. Cells were then resuspended in FACS buffer before acquisition All flow cytometry 655 acquisitions were realized using a Becton Dickinson 5 lasers LSR Fortessa X-20 and data analysis using 656 Flowjo vX (Treestar, BD Biosciences). For assessment of surface marker expression levels, ratios of 657 the geometric mean fluorescence intensity (gMFI) of the markers to the gMFI of the corresponding 658 isotype control were calculated and expressed in arbitrary units (A.U.).

659 **Kidney Immunofluorescence assays** 

660 4 µm thick cryosections of OCT-embedded kidneys were fixed 20 min in ice-cold acetone and kept a - 661 80°C until immunofluorescence staining. Slides were thawed and fixed in 10% formalin (Sigma) for 20 662 min at room temperature and blocked with PBS containing 1% BSA (Euromedex) and 5% goat serum 663 (Sigma-Aldrich). Slices were stained for 2 hours at room temperature in the dark in a humid chamber 664 with FITC-conjugated anti-mouse C3 (Cedarlane), Alexa Fluor® 488-conjugated anti-mouse C3 (Santa 665 Cruz Biotech), Alexa Fluor® 488-conjugated goat anti-mouse IgG Fcγ-specific (Jackson 666 Immunoresearch), FITC-conjugated goat anti-mouse IgM (BioRad (AbD Serotec)) or corresponding 667 isotype controls. Slides were mounted in Immunomount (Thermofischer Scientifics) and analyzed by 668 fluorescent microscopy (Leica DMR, Leica microsystems). The ratio of specific glomerular 669 fluorescence over tubulointerstitial background was then measured using ImageJ software v. 1.43u

670 (NIH), averaging at least 30 glomeruli per mouse for each sample.

### 671 **Anti-RNP IgG and IgM autoantibody detection**

672 Maxisorp 96 well plates (Thermo Scientific) were coated overnight at 4°C with 10 µg/mL of purified 673 RNP complexes (Immunovision) diluted in carbonate buffer (100 mM NaHCO<sub>3</sub> and 30 mM Na<sub>2</sub>CO<sub>3</sub> pH 674 9.6). Plates were washed 3 times in PBS containing 0.1% of Tween-20 (Bio-Rad laboratories) (PBS-T) 675 and saturated for 1 hour with PBS containing 5% of FCS. For anti-RNP IgG quantification, plasma 676 samples were diluted 1:25 in PBS-T containing 5% of goat serum and 100 µL added to the wells. 677 Samples, positive and negative controls were incubated for 2 hours at rt. Plates were washed 5 times 678 with PBS-T. 100 µL of either 500 ng/mL goat anti-mouse IgG (Invitrogen) or 10 ng/mL goat anti-679 mouse IgM (Bethyl laboratories) conjugated to horseradish peroxidase (HRP) diluted in PBS-T 680 containing 5% goat serum were added and incubated 1h at room temperature. After 5 washes in 681 PBS-T, 100 µL of tetramethylbenzidine (TMB) substrate (ThermoFisher) were added to the wells and 682 incubated at least 20 min at rt and the reaction was stopped with 0.2N sulfuric acid solution. Optical 683 density at 450 nm was measured by spectrophotometry (Infinite 200 Pro plate reader, TECAN). On 684 each plate, similar negative and positive controls were run. Optical density (OD) values were first

685 normalized to the negative controls and then, the presented results were normalized to the mean of 686 the control mice values and expressed in arbitrary units (A.U.).

### 687 **Anti-dsDNA IgG detection**

688 Maxisorp 96 well plates (Thermo Scientific) were coated overnight at 4°C with calf thymus dsDNA

689 (Sigma-Aldrich) diluted in TE buffer (Tris-HCl 10 mM, EDTA 1 mM pH 9) at a concentration of 2 µg/mL

690 and diluted in the same volume of Pierce DNA coating solution (Thermo Scientific) to obtain a final

691 concentration of 1 $\mu$ g/mL of dsDNA. The same protocol as for anti-RNP IgG was then followed but the

692 PBS-T contained 0.05% of Tween-20.

### 693 **Cell sorting and co-culture**

694 For mouse co-culture experiments, F(ab')2 anti-CD3 (clone145-2C11 at 0,5 µg/mL) and anti-CD28 695 (clone PV-1 at 0,5 µg/mL) antibodies (BioXcell) were coated overnight at 4°C in culture 96 well plates 696 (Costar) in sterile-filtered coating buffer (20 mM carbonate buffer (pH 9.6) containing 2 mM MgCl<sub>2</sub> 697 and 0.01% NaN3). Wells were washed in PBS before plating the cells. Spleens were harvested and 698 handled as described above and resuspended at  $10^8$  cells/mL in PBS containing 2% FCS and 2mM 699 EDTA. Naïve CD4<sup>+</sup> T cells were sorted by magnetic negative selection following manufacturer 700 protocol (Stemcell Technologies) and resuspended in culture medium at 0.5 million cells/mL. 100 µL 701 of naïve CD4+ T cell suspension were then added to wells of interest. Basophils from CTM8 mice were 702 purified over 98% by electronic sorting using the BD FACSMelody Cell Sorter (BD Biosciences) using 703 the tandem tomato fluorescent protein as a specific marker<sup>12</sup>. Basophils were re-suspended in 704 culture medium at 0.1 million cells/mL and 100µL were added to wells of interest. All wells were 705 supplemented with 10 pg/mL of recombinant mouse IL-3 (Peprotech). After 3 days of culture at 37°C 706 5% CO2, cells were harvested and prepared for flow cytometry as described above. For cytokine 707 production detection, cells were stimulated or not for the last 4 hours with 40 nM PMA and 800 nM 708 ionomycin in the presence of 2 µg/mL brefeldin A (Sigma-Aldrich, Merck) and prepared for flow 709 cytometry as described above.

710 For human co-culture experiments, 96 well plates (Costar) were coated overnight at 4°C in coating 711 buffer containing 5 µg/mL of mouse anti-human CD3 (clone OKT3) (Thermo Fischer Scientific). Blood 712 from healthy volunteers was handled and lysed as described above in sterile conditions and re-713 suspended at 5x10<sup>7</sup> cells/mL in PBS 2% FCS (Gibco) 2mM EDTA. Naïve CD4+ T cells and basophils 714 were sorted by magnetic negative selection following manufacturer instructions (Stemcell 715 Technologies). Naïve CD4<sup>+</sup> T cells were re-suspended in culture medium at 0.5 million cells/mL. and 716 100 µL of cell suspension were then added to each well. Basophils were resuspended in culture 717 medium at 0.1 million cells/mL and 100µL were added to each well unless otherwise specified. All 718 wells were supplemented with 10 pg/ml of recombinant human IL-3 (Biolegend) and 2 ug/mL of 719 mouse anti-human CD28 antibody (Clone CD28.2 at (BioXcell)). When indicated, some wells were 720 supplemented with mouse anti-human blocking antibodies targeting IL4 (Clone MP4-25D2), IL-6 721 (Clone MQ2-13A5), both at 5 µg/mL or PD-1 (Clone EH12.2H7 at 10µg/mL) or with the corresponding 722 isotypes at the same concentrations. Cells were harvested after 3 days of culture at 37°C 5% CO<sub>2</sub> and 723 prepared for flow cytometry as described above.

### 724 **Statistical analysis**

725 Two-tailed Student's unpaired t-tests were used to compare the differences of one variable between 726 two groups when distributions were Gaussian and Mann-Whitney U tests for non-parametric 727 distributions. When more than two groups were compared, one-way ANOVA coupled with *ad hoc* 728 multiple comparisons post-tests, as indicated in the figure legends depending on the distribution of 729 the values in each group, were used. Statistical analyses were realized using Prism v9.4 software 730 (Graphpad).

731 **Antibodies, reagents, software and equipments** 

732 See Supplementary Table S3.

It is made available under a CC-BY-NC-ND 4.0 International license.

### 734 **REFERENCES**





It is made available under a CC-BY-NC-ND 4.0 International license.

### 831 **FIGURES**

832 FIGURE 1



833

834 **Figure 1: Human blood basophils from SLE patients overexpress PD-L1** 

It is made available under a CC-BY-NC-ND 4.0 International license.

### 836 FIGURE 2



838 **Figure 2: Basophil-TFH functional relationship during lupus-like disease** 

839

It is made available under a CC-BY-NC-ND 4.0 International license.

### 840 FIGURE 3



841<br>842 842 **Figure 3: Basophils control TFH abilities to produce IL-21 and IL-4 in the lupus-like context**  843

It is made available under a CC-BY-NC-ND 4.0 International license.

### 844 FIGURE 4



845

**Figure 4: A bidirectional crosstalk between basophils and CD4<sup>+</sup>** 846 **T cells promotes** *ex vivo* **TFH** 

- 847 **differentiation**
- 848

It is made available under a CC-BY-NC-ND 4.0 International license.



851

852 **Figure 5: PD-L1 controls the basophil-TFH functional relationship during lupus-like disease**

It is made available under a CC-BY-NC-ND 4.0 International license.

### 854 FIGURE 6



855

856 **Figure 6: Basophil-derived IL-4 controls T-dependent autoreactive antibody isotype switch in lupus-**

- 857 **like disease**
- 858

It is made available under a CC-BY-NC-ND 4.0 International license.

859 FIGURE 7



861 **Figure 7: Human basophils drive TFH cell and TFH2 cell differentiation through IL-4, IL-6 and PD-1**  862 **dependent mechanisms** *ex vivo* 

It is made available under a CC-BY-NC-ND 4.0 International license.



866 Pathogenic accumulation of T follicular helper cells in lupus disease depends on PD-L1 and IL-4

867 expressing basophils.

868